These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 21187272)

  • 1. Mu-opioid and noradrenergic α(2)-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats.
    Bee LA; Bannister K; Rahman W; Dickenson AH
    Pain; 2011 Jan; 152(1):131-139. PubMed ID: 21187272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain.
    Schröder W; Vry JD; Tzschentke TM; Jahnel U; Christoph T
    Eur J Pain; 2010 Sep; 14(8):814-21. PubMed ID: 20541444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of μ-opioid and noradrenaline reuptake inhibition in the modulation of pain responsive neurones in the central amygdala by tapentadol in rats with neuropathy.
    Gonçalves L; Friend LV; Dickenson AH
    Eur J Pharmacol; 2015 Feb; 749():151-60. PubMed ID: 25576174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain.
    Schiene K; De Vry J; Tzschentke TM
    J Pharmacol Exp Ther; 2011 Nov; 339(2):537-44. PubMed ID: 21816956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid and noradrenergic contributions of tapentadol in experimental neuropathic pain.
    Meske DS; Xie JY; Oyarzo J; Badghisi H; Ossipov MH; Porreca F
    Neurosci Lett; 2014 Mar; 562():91-6. PubMed ID: 23969300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.
    Largent-Milnes TM; Guo W; Wang HY; Burns LH; Vanderah TW
    J Pain; 2008 Aug; 9(8):700-13. PubMed ID: 18468954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spinal-supraspinal and intrinsic μ-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice.
    Christoph T; Schröder W; Tallarida RJ; De Vry J; Tzschentke TM
    J Pharmacol Exp Ther; 2013 Dec; 347(3):794-801. PubMed ID: 24051022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of tapentadol on neurons in the locus coeruleus.
    Torres-Sanchez S; Alba-Delgado C; Llorca-Torralba M; Mico JA; Berrocoso E
    Neuropharmacology; 2013 Sep; 72():250-8. PubMed ID: 23664814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia.
    Schröder W; Tzschentke TM; Terlinden R; De Vry J; Jahnel U; Christoph T; Tallarida RJ
    J Pharmacol Exp Ther; 2011 Apr; 337(1):312-20. PubMed ID: 21262850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the norepinephrine transporter (NET) inhibition on μ-opioid receptor (MOR)-induced anti-nociception in a bone cancer pain model.
    Ono H; Nakamura A; Kanbara T; Minami K; Shinohara S; Sakaguchi G; Kanemasa T
    J Pharmacol Sci; 2014; 125(3):264-73. PubMed ID: 24965165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual μ-opioid receptor and norepinephrine reuptake mechanisms contribute to dezocine- and tapentadol-induced mechanical antiallodynia in cancer pain.
    Mao XF; Ahsan MZ; Apryani E; Tang XQ; Zhao MJ; Li XY; Wang YX
    Eur J Pharmacol; 2020 Jun; 876():173062. PubMed ID: 32173379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spinal neuronal correlates of tapentadol analgesia in cancer pain: a back-translational approach.
    Falk S; Patel R; Heegaard A; Mercadante S; Dickenson AH
    Eur J Pain; 2015 Feb; 19(2):152-8. PubMed ID: 24917026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.
    Tzschentke TM; Christoph T; Kögel B; Schiene K; Hennies HH; Englberger W; Haurand M; Jahnel U; Cremers TI; Friderichs E; De Vry J
    J Pharmacol Exp Ther; 2007 Oct; 323(1):265-76. PubMed ID: 17656655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depression of C fibre-evoked spinal field potentials by the spinal delta opioid receptor is enhanced in the spinal nerve ligation model of neuropathic pain: involvement of the mu-subtype.
    Buesa I; Urrutia A; Aira Z; Salgueiro M; Bilbao J; Mozas M; Aguilera L; Zimmermann M; Azkue JJ
    Neuropharmacology; 2008 Dec; 55(8):1376-82. PubMed ID: 18775732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The roles of different subtypes of opioid receptors in mediating the nucleus submedius opioid-evoked antiallodynia in a neuropathic pain model of rats.
    Wang JY; Zhao M; Yuan YK; Fan GX; Jia H; Tang JS
    Neuroscience; 2006; 138(4):1319-27. PubMed ID: 16472929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tapentadol: with two mechanisms of action in one molecule effective against nociceptive and neuropathic pain. Preclinical overview].
    Tzschentke TM; Christoph T; Schröder W; Englberger W; De Vry J; Jahnel U; Kögel BY
    Schmerz; 2011 Feb; 25(1):19-25. PubMed ID: 21258822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antinociceptive and antihyperalgesic effect of tapentadol is partially retained in OPRM1 (μ-opioid receptor) knockout mice.
    Kögel B; De Vry J; Tzschentke TM; Christoph T
    Neurosci Lett; 2011 Mar; 491(2):104-7. PubMed ID: 21232580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tapentadol, but not morphine, selectively inhibits disease-related thermal hyperalgesia in a mouse model of diabetic neuropathic pain.
    Christoph T; De Vry J; Tzschentke TM
    Neurosci Lett; 2010 Feb; 470(2):91-4. PubMed ID: 20026182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffuse noxious inhibitory controls and nerve injury: restoring an imbalance between descending monoamine inhibitions and facilitations.
    Bannister K; Patel R; Goncalves L; Townson L; Dickenson AH
    Pain; 2015 Sep; 156(9):1803-1811. PubMed ID: 26010460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid and noradrenergic contributions of tapentadol to the inhibition of locus coeruleus neurons in the streptozotocin rat model of polyneuropathic pain.
    Torres-Sanchez S; Borges GDS; Mico JA; Berrocoso E
    Neuropharmacology; 2018 Jun; 135():202-210. PubMed ID: 29551688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.